Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, shares his insights on iPSC-MSC therapy for inflammatory diseases. He discusses Kiji's innovative approach to tackling conditions like graft-versus-host disease, inflammatory bowel disease, and psoriasis through advanced clinical trials. The conversation highlights the significance of strategic funding and global collaboration in biotechnology. Forte also reflects on the opportunities presented at ARM's meeting and the importance of networking for future technological advancements.